tradingkey.logo

Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor

ReutersMay 30, 2025 12:51 PM

- Merck & Co Inc MRK.N:

  • MERCK ANNOUNCES MK-1084, AN INVESTIGATIONAL KRAS G12C INHIBITOR, SHOWS ANTITUMOR ACTIVITY IN PHASE 1 TRIAL OF PATIENTS WITH ADVANCED COLORECTAL CANCER AND NON-SMALL CELL LUNG CANCER WHOSE TUMORS HARBOR KRAS G12C MUTATIONS

  • MERCK & CO INC - MK-1084 TO BE INVESTIGATED IN PHASE 3 KANDLELIT-012 AND KANDLELIT-004 STUDIES

  • MERCK & CO INC - MK-1084 SHOWS MANAGEABLE SAFETY PROFILE AND ANTITUMOR ACTIVITY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI